Injectable semaglutide (Novo Nordisk) is a once-weekly glucagon-like peptide-1 (GLP-1) agonist currently seeking approval for the treatment of type 2 diabetes. It is a sustained-release formulation GLP-1 agonist and therefore acts on the incretin system. Semaglutide is structurally similar to Victoza (liraglutide; Novo Nordisk), with two modifications: Gly in position eight is replaced by Aib, and the fatty acid side chain has been modified to bind to albumin in circulation to prolong semaglutide’s half-life. This increased half-life allows for once-weekly dosing.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 semaglutide (Injectable) : Diabetes type 2
LIST OF FIGURES 9 Figure 1: Injectable semaglutide for type 2 diabetes – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of injectable semaglutide for type 2 diabetes
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of injectable semaglutide for type 2 diabetes
LIST OF TABLES 6 Table 2: Injectable semaglutide Phase III data in type 2 diabetes
14 Table 2: Injectable semaglutide sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726